Revolution Medicines/$RVMD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Revolution Medicines
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
Ticker
$RVMD
Sector
Primary listing
Employees
700
Headquarters
Website
RVMD Metrics
BasicAdvanced
$11B
-
-$4.53
1.16
-
Price and volume
Market cap
$11B
Beta
1.16
52-week high
$60.59
52-week low
$29.17
Average daily volume
2.2M
Financial strength
Current ratio
11.794
Quick ratio
11.581
Long term debt to equity
6.417
Total debt to equity
7.119
Profitability
EBITDA (TTM)
-890.7
Effective tax rate (TTM)
0.09%
Management effectiveness
Return on assets (TTM)
-26.47%
Return on equity (TTM)
-46.61%
Valuation
Price to book
5.87
Price to tangible book (TTM)
6.1
Price to free cash flow (TTM)
-15.007
Free cash flow yield (TTM)
-6.66%
Free cash flow per share (TTM)
-3.903
Growth
Earnings per share change (TTM)
26.53%
3-year earnings per share growth (CAGR)
14.24%
What the Analysts think about RVMD
Analyst ratings (Buy, Hold, Sell) for Revolution Medicines stock.
Bulls say / Bears say
Revolution Medicines dosed the first patient in its global Phase 3 RASolve 301 trial evaluating daraxonrasib in previously treated RAS-mutant NSCLC on May 14, 2025, moving a key program forward toward pivotal results (GlobeNewswire).
The U.S. FDA granted Breakthrough Therapy Designation to daraxonrasib for previously treated metastatic pancreatic ductal adenocarcinoma on June 23, 2025, which may accelerate its development and review process (GlobeNewswire).
Revolution Medicines secured up to $2 billion in flexible funding from Royalty Pharma on June 24, 2025, strengthening its financial position to back global development and commercialization efforts for its RAS(ON) inhibitor portfolio (Royalty Pharma).
Revolution Medicines reported a net loss of $213.4 million in Q1 2025 and is projecting a full-year 2025 GAAP net loss of $840 million to $900 million, indicating a high cash burn that could require additional funding if pivotal trials are delayed (NatLawReview).
Research and development expenses grew to $224.1 million in Q2 2025, up from $134.9 million a year prior, pushing the full-year net loss outlook to $1.03 billion-$1.09 billion and raising sustainability concerns as the company remains pre-revenue (BeyondSPX).
Major Phase 3 trial results for daraxonrasib in metastatic pancreatic and non-small cell lung cancer are expected only in 2026, meaning RVMD faces binary event risk without any near-term commercial products (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
RVMD Financial Performance
Revenues and expenses
RVMD Earnings Performance
Company profitability
RVMD News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Revolution Medicines stock?
Revolution Medicines (RVMD) has a market cap of $11B as of November 05, 2025.
What is the P/E ratio for Revolution Medicines stock?
The price to earnings (P/E) ratio for Revolution Medicines (RVMD) stock is 0 as of November 05, 2025.
Does Revolution Medicines stock pay dividends?
No, Revolution Medicines (RVMD) stock does not pay dividends to its shareholders as of November 05, 2025.
When is the next Revolution Medicines dividend payment date?
Revolution Medicines (RVMD) stock does not pay dividends to its shareholders.
What is the beta indicator for Revolution Medicines?
Revolution Medicines (RVMD) has a beta rating of 1.16. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.